This Funding Opportunity Announcement (FOA) encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.
This FOA runs in parallel with an FOA of identical scientific scope, PAR-22-219 , which utilizes the Exploratory/Developmental Grant (R21) mechanism.
Deadlines:
PAR-22-218 Expiration Date September 08, 2025
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Oct 05, 2024
Varies
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.